title: Effect of nipradilol on myocardial energy metabolism in the dog ischaemic heart.
abstract: The effect of nipradilol, a newly developed beta-adrenoceptor blocking agent with a vasodilatory action, on myocardial energy metabolism has been examined in the dog ischaemic heart, and compared with that of propranolol. Ischaemia was induced by ligating the left anterior descending coronary artery. Either saline, nipradilol (0.3 mg kg-1), or propranolol (1 mg kg-1) was injected intravenously 5 min before coronary ligation. After 3 or 30 min of coronary ligation, the ischaemic region of the myocardium was removed, and the endocardial portion used to determine the levels of adenosine triphosphate (ATP), adenosine diphosphate (ADP), adenosine monophosphate (AMP), creatine phosphate (CrP) and lactate. Ischaemia decreased the levels of ATP and CrP, and increased the levels of ADP, AMP and lactate. Immediately after the injection of nipradilol, rapid falls in blood pressure and heart rate were observed. Pretreatment with nipradilol lessened the decreases in the levels of ATP and CrP and the increases in the levels of AMP and lactate, caused by 3 min of ischaemia, to the same extent as propranolol. However, after 30 min of ischaemia, nipradilol had no effect on myocardial metabolism unlike propranolol. These results indicate that nipradilol can reduce ischaemic influences on myocardial metabolism as well as propranolol, but only in the early stages of ischaemia.
authors.affiliation: Department of Hospital Pharmacy, Asahikawa Medical College, Japan.
authors.forename: N
authors.initials: N
authors.lastname: Hayase
authors.forename: K
authors.initials: K
authors.lastname: Chiba
authors.forename: K
authors.initials: K
authors.lastname: Ichihara
authors.forename: S
authors.initials: S
authors.lastname: Inagaki
authors.forename: Y
authors.initials: Y
authors.lastname: Abiko
mesh_terms: D000227:Adenine Nucleotides / Q000378:metabolism; D000319:Adrenergic beta-Antagonists / Q000494:pharmacology*; D000818:Animals; D001794:Blood Pressure / Q000187:drug effects; D003326:Coronary Circulation / Q000187:drug effects; D003327:Coronary Disease / Q000378:metabolism*; D004285:Dogs; D004734:Energy Metabolism / Q000187:drug effects*; D005260:Female; D006321:Heart / Q000187:drug effects*; D006339:Heart Rate / Q000187:drug effects; D007773:Lactates / Q000378:metabolism; D008297:Male; D009206:Myocardium / Q000378:metabolism*; D010725:Phosphocreatine / Q000378:metabolism; D011412:Propanolamines / Q000494:pharmacology*
chemical_list: D000227:Adenine Nucleotides; D000319:Adrenergic beta-Antagonists; D007773:Lactates; D011412:Propanolamines; D010725:Phosphocreatine; C036089:nipradilol